INTRODUCTION
============

Tuberculosis (TB) is one of the major public health problems in Democratic People\'s Republic of Korea (North Korea). The estimated incidence of TB is 442/100,000 population ([@B1]). Although no nationwide epidemiological data have been obtained yet, drug-resistant TB can be the most important hurdle in TB control in North Korea. Given very limited second-line drugs (SLDs) supplies, only a small portion of patients can be treated with SLD through the Global Drug Facility (GDF) under the Programmatic Management of Drug-resistant TB (PMDT) which started in 2012 ([@B2]) or the Eugene Bell Foundation (EBF) which commenced in 2008 ([@B3]). Therefore, most patients, even those who failed with the category II drug treatment and those suspected for multidrug-resistant (MDR)-TB, would be repeatedly treated with first-line drugs especially before 2008. Therefore, the resistance distribution can be different in other regions of the world or from our expectation.

The treatment success of new sputum smear-positive patients has consistently exceeded 80% since 2001 and 90% since 2009, after the Ministry of Public Health (MOPH) adopted directly observed therapy short course (DOTS) in North Korea in 1998 ([@B2]) with the help of international aids including the Global Fund to Fight AIDS, TB and Malaria (GFATM) and United Nations Children\'s Fund (UNICEF) ([@B2]). However, few of these international aids have included treatment for drug-resistant TB. A national or subnational drug resistance survey has not been performed in North Korea yet. However, limited drug resistance surveillance survey was conducted recently in North Hwanghae Province. The interim results of this limited survey showed that rifampicin (RIF) resistance was detected in 2.2% and 16.3% of new and previously treated smear-positive patients, respectively ([@B2]). Therefore, we can assume that significant number of MDR-TB patients exist in North Korea.

The EBF requested the Clinical Research Center of the Masan National Tuberculosis Hospital (MNTH) for culture and drug susceptibility test (DST) of sputum specimens obtained from TB patients in the sanatoria of North Korea from 2007 to 2009. The EBF is a United States and Republic of Korea (South Korea) based non-governmental organization that supports for diagnosis and treatment of MDR-TB and drug-susceptible TB patients in the sanatoria that spans North Korea ([@B4]). EBF has been visiting each center once every 6 months to deliver sputum samples for DST since 2007 ([@B5]), and supplying SLD to North Korea since 2008.

This study aims to analyze the drug resistance patterns of *Mycobacterium tuberculosis* isolated from the sputum samples of the patients who were recorded to be untreated with SLD in the sanatoria of North Korea, during the period when SLD was not officially supplied to North Korea.

MATERIALS AND METHODS
=====================

Collection and transfer of sputum specimens
-------------------------------------------

The EBF staff visited North Korean sanatoria and delivered sputum specimens of TB patients to the MNTH every 6 months from 2007 to 2009. The sanatoria (n = 17) were located in the capital city area and rural areas close to the border to China and South Korea. Before each EBF visit, potential candidates for MDR-TB are selected by the sanatorium staff from those who have failed to respond to the standard DOTS regimens (category I or II). The EBF staff registered the patients by taking photos with name, sex, and age of each patient for identification purposes and recorded the clinical information of the patients. However, not all patients provided these data.

Because the period from sputum collection to culture took approximately over 2 weeks, the following protocol was applied to improve bacterial viability. Sputum specimens were collected in 50 mL conical tubes and mixed with equal volume of 1% (w/v) cetylpyridinium chloride (Sigma-Aldrich, St. Louis, MO, USA) for decontamination and were shaken by hand ([@B6]-[@B8]). Subsequently, the sputum specimens were kept in room temperature and transferred to the MNTH when the EBF staff returned to South Korea. The average time interval between sputum sampling and transfer to the MNTH was 11.4 (range of 5--20) days.

Pretreatment and acid-fast bacillus stain/culture
-------------------------------------------------

After transfer to the MNTH, the sputum specimens were neutralized with the same volume of neutralizing buffer (Difco™; Becton, Dickinson and Company, Detroit, MI, USA) as recommended by the manufacturer and centrifuged at 5,000 × g for 10 minutes. After discarding the supernatant, the pellet was resuspended with 1 mL phosphate-buffered saline (pH 6.8). Exactly 100 µL of the resuspension was plated on 3% Ogawa slant culture medium. The plated culture media were placed in a 37°C incubator and observed daily. Culture negative was defined if the absence of organism growth after 8 weeks ([@B9]).

Cultured organisms were confirmed as *M. tuberculosis* via TB antigen testing using SD BIOLINE TB Ag MPT64 Rapid^®^ Kit (SD BIOLINE; Standard Diagnostics, Inc., Yongin, Korea). Negative result on TB Ag MPT64 and growth of bacterial colonies on the paranitrobenzoic acid containing Löwenstein-Jensen (L-J) medium was considered as nontuberculous mycobacteria.

DST in L-J medium
-----------------

Culture-based conventional phenotypic DST was performed using the absolute concentration method in L-J medium, which was commercially provided by the Korean Institute of Tuberculosis (Osong, Korea) based on the manufacturer\'s instructions. The critical drug concentrations were set by following the World Health Organization\'s (WHO) guideline; 0.2 µ/mL isoniazid (INH), 40.0 µ/mL RIF, 2.0 µ/mL ethambutol (EMB), 10.0 µ/mL streptomycin (S), 40.0 µ/mL injectable drugs (IDs) (kanamycin \[Km\], amikacin \[Am\], and capreomycin \[Cm\]), 2.0 µ/mL fluoroquinolones (FQs) (ofloxacin \[Ofx\] and moxifloxacin \[Mfx\]), 1.0 µ/mL para-aminosalicylic acid (PAS), 40.0 µ/mL ethionamide (Eto), and 30.0 µ/mL cycloserine (Cs). Bacterial growth was checked every week. The growth of *M. tuberculosis* was confirmed using TB Ag MPT64 Rapid^®^ Kit (Standard Diagnostics, Inc.). *M. tuberculosis* was confirmed to be resistant when it grew in the drug-containing medium and as sensitive in the absence of bacterial growth for 8 weeks. The resistance of *M. tuberculosis* strains to pyrazinamide (PZA) was tested using pyrazinamidase assay.

We analyzed the DST results of *M. tuberculosis* strains isolated from the patients\' sputum specimens that were transferred only for the first time to exclude the effects of SLD supplied by the EBF. The EBF started to treat the patients with the regimen prescribed based on the DST data that included SLD. To eliminate the presence of any possible effects of the treatment on the drug resistance patterns of TB, *M. tuberculosis* strains isolated for the second time or more from the same patients were excluded in this study. Therefore, the DST results in this study were for *M. tuberculosis* strains that were isolated from the patients who may have not been treated with SLD before.

Statistical analysis
--------------------

The statistical significance was analyzed through χ^2^ test using GraphPad InStat software (version 3.0; GraphPad Software, Inc., La Jolla, CA, USA). *P* values \< 0.05 were considered as significantly different.

Ethics statement
----------------

The EBF staff collected sputum samples from patients in the sanatoria and transferred these samples to the MNTH for isolation and DST of *M. tuberculosis* strains from 2007 to 2009 for treatment purposes. Considering that the culture and DST results of the *M. tuberculosis* strains isolated from the sputum samples were retrospectively analyzed, this research was approved by the Institutional Review Board of the MNTH (IRB-12-N02) with the exemption of informed consent.

RESULTS
=======

Culture and DST results of patients in the sanatoria of North Korea
-------------------------------------------------------------------

The EBF staff visited 17 sanatoria in North Korea every 6 months for a total of 5 times from 2007 to 2009. They delivered 947 sputum specimens from 667 patients (male/female ratio = 464:203, mean age = 46 ± 22 years). Four hundred ninety-two patients were culture positive (73.8%) based on the sputum specimens collected for the first time. Among the 492 patients, 163 patients (33.1%) were culture positive based on sputum specimens collected for the second or third time. The DST analysis was performed for *M. tuberculosis* strains isolated for the first time from 489 patients because the specimens collected from 3 patients were excluded given the absence of bacterial growth during DST or contamination.

In North Korea, the resistance rate to category I and II drugs (INH, RIF, EMB, and S) was considerably higher than that of other drugs (IDs and FQs) as described in [Fig. 1A](#F1){ref-type="fig"} which shows the resistance rate for the first- and second-line anti-TB drugs. Furthermore, 463 (94.7%) and 380 (77.7%) patients had resistance to INH and RIF, respectively. The RIF resistance rate was lower than that of INH. Resistance to EMB and S was also found in 232 (47.4%) and 362 (74.0%) patients, respectively. For IDs, the resistance rate for Km was 11.9%, whereas that for Am and Cm was 9.2%. The FQ resistance rates were very low. Specifically, the Ofx and Mfx resistance rates were 2.5% and 1.4%, respectively.

![Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (**A**) patients (n = 489) in all sanatoria analyzed in this study, (**B**) patients (n = 263) in region A, (**C**) patients (n = 108) in sanatoria located in region B, and (**D**) patients (n = 118) in region C. *M.* *tuberculosis* strains were isolated from the first sputum samples of each patient and used for DST as described in the text.\
Region A = the capital city area, Region B = North Pyongan Province, Region C = South Pyongan and Hwanghae Provinces, DST = drug susceptibility test, TB = tuberculosis, INH = isoniazid, RIF = rifampicin, EMB = ethambutol, PZA = pyrazinamide, S = streptomycin, Km = kanamycin, Am = amikacin, Cm = capreomycin, Ofx = ofloxacin, Mfx = moxifloxacin, PAS = para-aminosalicylic acid, Eto = ethionamide, Cs = cycloserine.](jkms-32-1105-g001){#F1}

Regional differences of anti-TB drug resistance patterns
--------------------------------------------------------

[Fig. 1B-D](#F1){ref-type="fig"} show the regional differences of resistance pattern. The sanatoria (n = 4) in the region of the capital city area were designated as region A ([Fig. 1B](#F1){ref-type="fig"}), those (n = 5) located in North Pyongan Province were designated as region B ([Fig. 1C](#F1){ref-type="fig"}), those (n = 8) in South Pyongan and Hwanghae Provinces were designated as region C ([Fig. 1D](#F1){ref-type="fig"}). The INH resistance rate was high (\> 92.0%) in all regions (*P* = 0.268). The RIF resistance rates were high in regions A and B, which were 81.7% and 84.3%, respectively. However, the RIF resistance rate in region C (62.7%) was significantly lower than the rates in the other 2 regions (*P* \< 0.001). The EMB resistance rate in region C (29.7%) was also lower than the rates in regions A (52.9%) and B (53.7%) (*P* \< 0.001). For PZA, the resistance rate in region C (0%) was lower than that of region A (6.8%) (*P* = 0.011). However, no significant difference was observed in PZA resistance rates between regions B and C or regions A and B. The resistance rates for IDs (Km, Am, and Cm) in region B were higher than the rates in other regions. That is, the resistance rate to Km was higher in region B (17.6%) than region C (6.8%) (*P* = 0.043), although no significant difference was observed between regions A (11.8%) and C. Other IDs besides Km (Am and Cm) also seemed to show higher resistance rates in region B (13.9% and 12.0%, respectively) than regions A (8.4% and 8.0%, respectively) and C (6.8% and 9.3%, respectively), although there was no statistical significance.

FQ (Ofx and Mfx) resistance was not found in region C. Region B showed very low resistance rates to FQ (1.9% and 0.9% for Ofx and Mfx, respectively). FQ resistance rates in big city regions (region A: 3.8% and 2.3%) tended to be higher than other regions, although no statistically significant difference was detected.

In this study, the number of MDR-TB in the sanatoria in North Korea was 376 ([Table 1](#T1){ref-type="table"}), which accounted for 76.9% of the total 489 patients. Regions A and B showed higher MDR rate (81.4% and 82.4%, respectively) than region C (61.9%) (*P* \< 0.001). Among MDR-TB found in North Korea in this study, resistance to at least one of IDs was regionally different (*P* = 0.039); highest in region B (18.5%), and lowest in region C (5.1%). Additionally, FQ resistant among MDR-TB patients was not seen in region C. Interestingly, 2 extremely drug-resistant (XDR)-TB patients were individually found in regions A and B, even before official supply of SLD in North Korea ([Table 1](#T1){ref-type="table"}).

###### The number of drug-resistant isolates by region of North Korea

![](jkms-32-1105-i001)

  Resistance patterns   Drug-resistant isolates by region (%)                            
  --------------------- --------------------------------------- ------------ ----------- -----------
  All susceptible       16 (3.3)                                7 (2.7)      2 (1.9)     7 (5.9)
  INH mono resistant    23 (4.7)                                11 (4.2)     0 (0)       12 (10.2)
  RIF mono resistant    0 (0)                                   0 (0)        0 (0)       0 (0)
  S mono resistant      5 (1.0)                                 2 (0.8)      3 (2.8)     0 (0)
  MDR                   376 (76.9)                              214 (81.4)   89 (82.4)   73 (61.9)
  MDR + ID resistant    57 (11.7)                               31 (11.8)    20 (18.5)   6 (5.1)
  MDR + FQ resistant    10 (2.0)                                8 (3.0)      2 (1.9)     0 (0)
  XDR                   2 (0.4)                                 1 (0.4)      1 (0.9)     0 (0)

A = the capital city area, B = North Pyongan Province, C = South Pyongan and Hwanghae Provinces, INH = isoniazid, RIF = rifampicin, S = streptomycin, MDR = multidrug-resistant, ID = injectable drug, FQ = fluoroquinolone, XDR = extremely drug-resistant.

DISCUSSION
==========

Most patients with pulmonary TB in the sanatoria of North Korea who failed category I or II drug treatment were MDR-TB patients. Over 3 quarters of the suspected cases were, in fact, MDR-TB. *M. tuberculosis* strains which were obtained from the patients in the sanatoria had high resistance rates for INH, RIF, EMB, and S, but only low resistance rate for FQs. Furthermore, significant regional differences were observed in the resistance rates for RIF, FQs, and IDs. Big city regions had higher resistance rates for RIF, FQs, and IDs except for S than the rural areas.

In this study, the INH resistance rate was over 90%, and the RIF and S resistance rates were over 70%. The fact that these were the only drugs supplied to North Korea may be one of the reasons for these high resistance rates to first-line drugs ([@B10]). Currently, the Global Fund allocates major budget for TB control in North Korea. GDF, a WHO-led initiative that has supplied high-quality drugs to over 90 countries provide treatment kits for adults in North Korea. The GDF standard treatment kit for new patients (category I) consists of 2 months of INH, RIF, EMB, and PZA, followed by 4 months of INH and RIF. The retreatment kit (category II) consists of 2 months of S injections plus INH, RIF, EMB, and PZA, followed by 1 month of INH, RIF, EMB, and PZA and 5 months of INH, RIF, and EMB. Therefore, the patients had to be repeatedly treated with first-line drugs even after failure of treatment. North Korea reported 85,564 new TB patients in 2011, the vast majority of whom would have received the GDF standard treatment kit for new patients (category I). Additionally, 13,507 patients with a history of TB treatment would have also received the GDF standard retreatment kit (category II) ([@B4]). Therefore, a significant portion of patients who received category II drugs can be assumed to already be suffering from MDR-TB; hence, the drugs were less effective. The EBF started to supply SLD since 2008 and PMDT has also been supplying SLD since June 2012 ([@B2]). This study was performed in the time period between 2007 and 2009 during which SLD were hardly supplied. Even after the EBF supplied SLD, the sputum specimens were collected at the sanatoria where SLD were not provided yet.

In this study (n = 489), the resistance to INH, RIF, EMB, and S was found in 463 (94.7%), 380 (77.7%), 232 (47.4%), and 362 (74.0%) patients, respectively. On the contrary, the SLD resistance rate was very low. We could not directly compare the resistance rates between North and South Korea, because most of South Korean data included all patients with TB and the data of this study represented the patients who failed the first-line drug treatment. However, North Korea showed a considerably larger difference in resistance rate between first-line drugs and SLD than South Korea ([@B11]).

These high resistance rates to first-line drugs were similar to those in the report of Seung and Linton in 2013 ([@B4]). However, they reported that the Ofx resistance rate was 11% which is significantly higher than the result of this study (2.5%). The difference can be attributed to the fact that SLD was supplied since 2008. They evaluated the resistance pattern from April 2010 to April 2011. However, the period of this study is from 2007 to 2009 and sputum specimens were collected from patients who were recorded to be untreated with SLD. That is, in this study, we evaluated the DST results of *M. tuberculosis* strains isolated from sputum specimens that were only collected for the first time to exclude the effects of SLD supplied by the EBF. Therefore, the resistance pattern would become more variable when the supply of SLD increases and rapid and exact DST for the first-line drugs and SLD would be needed.

The drug resistance pattern of TB shown in this study cannot represent the actual state of the pattern in North Korea. However, this drug resistance pattern suggests that MDR-TB in the sanatoria would be very serious and the TB patients who have failed the standard DOTS regimen would take SLD by informal systems ([@B4]). Especially, the patients in the capital city area (region A) and close to the border of China (region B) can be speculated to have easier access to SLD than those in relatively isolated area (region C) when considering the resistance rates of SLD and detection of XDR-TB patients ([Table 1](#T1){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}).

In North Korea, one of the major problems in TB control is unavailability of consistently proficient culture and DST laboratories ([@B2]). These are necessary to treat drug-resistant TB with effective individualized regimen, especially when drug resistance patterns can be more variable in the future.

Although PZA is a member of category I and II drugs, resistance to PZA was very low (22 isolates, 4.5%). The reason for this low resistance is not definite although, the possible cause could be the short period of exposure or laboratory methods. The high resistance rate to S and the low resistance rate to other IDs and FQs were associated with S being provided as category II drug and other IDs and FQs not being officially supplied to North Korea during the period of this study. Although, FQ resistance rate was generally very low, regional variations were observed. The resistance to these drugs seemed to be higher in large city than those in other relatively rural areas. Region C (southern part of North Korea) had lower MDR-TB rate than the other regions. The exact reason has not been well evaluated. However, we can postulate that one of the reasons is that patients who live in big cities can have more chances of exposure to these drugs.

A few limitations exist in this study. First, the results of this study cannot be generalized to estimate the exact drug resistance pattern of all TB patients in North Korea or even in the sanatoria, because MDR-TB patients were selected and registered for sputum collection from those who have failed to respond to the standard DOTS regimens (category I or II). Moreover, clear and specific criteria for patient selection were not developed. Second, little clinical information of the patients was available. Additionally, no data was available even on the previous regimens, and number of previous treatments. However, the resistance pattern found in this study is still valuable information because only little data on drug-resistant TB in North Korea exist.

In conclusion, small but significant regional variations in resistance pattern of *M. tuberculosis* from the sanitaria in North Korea were observed. The INH and RIF resistance rates were especially high at 94.7% and 77.7%, respectively. On the other hand, the resistance rates for FQ and IDs except for S were very low. However, this study was performed only for selected patients in the sanatoria in North Korea. Therefore, further studies are needed to evaluate the exact resistance pattern of TB in North Korea.
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